|
|||||
|
|
Phase 2 trial of high‐dose rituximab with high‐dose cytarabine mobilization therapy and high‐dose thiotepa,busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non‐Hodgkin lymphoma |
|
| Authors: | Yi‐Bin Chen MD Tracy Batchelor MD MPH Shuli Li MD Ephraim Hochberg MD Mark Brezina MD Sooae Jones NP Candice Del Rio RN Morgan Curtis MD Karen K. Ballen MD Jeffrey Barnes MD PhD Andrew S. Chi MD PhD Jorg Dietrich MD PhD Jessica Driscoll NP Elizabeth R. Gertsner MD Fred Hochberg MD Ann S. LaCasce MD Steven L. McAfee MD Thomas R. Spitzer MD Lakshmi Nayak MD Philippe Armand MD PhD |
| Affiliation: | 1. Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts;2. Division of Neuro‐Oncology, Massachusetts General Hospital, Boston, Massachusetts;3. Department of Biostatistics and Computational Biology, Dana‐Farber Cancer Institute, Boston, Massachusetts;4. Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts;5. Division of Hematological Malignancies, Dana‐Farber Cancer Institute, Boston, Massachusetts;6. Division of Neuro‐Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts |
| Abstract: | |
| Keywords: | autologous transplant central nervous system (CNS) lymphoma rituximab thiotepa busulfan cyclophosphamide (TBC) thiotepa |